Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Spencer, Jessica B ^a   Browne, Aimee S ^a   Copland, Susannah D ^b   Session, Donna R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; LUTEINIZING HORMONE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PROGESTERONE BLOOD LEVEL; PROGNOSIS; CASE CONTROL STUDY; COMPARATIVE STUDY; CYTOLOGY; DRUG ADMINISTRATION; DRUG EFFECT; EVALUATION; METHODOLOGY; OOCYTE; OVULATION INDUCTION; PREGNANCY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERTILIZATION IN VITRO; HUMANS; LUTEINIZING HORMONE; OOCYTE RETRIEVAL; OOCYTES; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 77952935549     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-29     Document Type: Article

References (12)

1. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P, Jayot S, Hugues JN. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004, 19:1979-1984. 10.1093/humrep/deh369, 15192072.
2. Franco JG, Baruffi RL, Oliveira JB, Mauri AL, Petersen CG, Contart P, Felipe V. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reprod Biol Endocrinol 2009, 7:58. 10.1186/1477-7827-7-58, 2701434, 19497101.
3. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004, 8:175-182.
4. Nyboeandersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsbøll S, Rasmussen PE, Lindenberg S, Bredkjaer HE, Meinertz H, Nordic LH, . study group Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod 2008, 23(2):427-434. 10.1093/humrep/dem317, 18024487, study group.
5. DePlacido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, Ranieri A, Colacurci N, Mollo A, . on behalf of the Italina Collaborative Group on Recombinant Human Luteinizing Hormone Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005, 20:390-396. 10.1093/humrep/deh625, 15576390, on behalf of the Italina Collaborative Group on Recombinant Human Luteinizing Hormone.
6. Perraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004, 82:1521-1526. 10.1016/j.fertnstert.2004.06.041, 15589853.
7. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005, 83:309-315. 10.1016/j.fertnstert.2004.07.969, 15705367.
8. Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A, . on behalf of the Recombinant LH Study Group Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod 2005, 20:629-635. 10.1093/humrep/deh682, 15618252, on behalf of the Recombinant LH Study Group.
9. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT, . on behalf of the Recombinant LH Study Group Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and II anovulation. Hum Reprod 2003, 18:314-322. 10.1093/humrep/deg066, 12571167, on behalf of the Recombinant LH Study Group.
10. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, Tarlatzis BC. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007, 13(5):445-452. 10.1093/humupd/dmm008, 17586849.
11. Kovacs P, Kovats T, Kaali SG. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertil Steril 2010, 93(2):475-479. 10.1016/j.fertnstert.2008.12.010, 19200991.
12. Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 2002, 17:3129-3137. 10.1093/humrep/17.12.3129, 12456612.